Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Birchtech Corp (BCHT)
AMEXHealth CareIndustrial - Pollution & Treatment ControlsSnapshot 2026-11-04
$1.10-1.79%
Close 2026-11-04 · 1-day change
AMEXHealth CareIndustrial - Pollution & Treatment ControlsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
0.05 → 0.05 EPS · FY ending Dec 31, 2027 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for BCHT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Free cash flow must improve | A supporting condition in Birchtech Corp's published investment case. The stated target is >=0% FCF. | Under Pressure | remains negative next fiscal year | Free cash flow: $-2.912M FY2026-Q2; GAAP. Published target: >=0% FCF. Target and observation units differ. Jun 30, 2026-2,912,200 USD · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making company rather than a proven durable compounder. Its long-term thesis is still intact, though the overall signal has shifted from mildly favorable to mixed.
The evidence labels BCHT cheap versus peers, but the valuation model has low confidence and the expectations gap is negative. Pricing is tagged as justified, with no identified fragility flags, so the apparent discount does not by itself show that expectations are undemanding.
Recent financial performance is neutral and ranks in the top half of the industry, but BCHT remains loss-making. Near term, the risk of missing earnings is elevated because it is a smaller company with consecutive misses; management has also seen CEO and CFO transitions, both classified as neutral.
Near-term conditions depend partly on employment: continued weakening in the jobs report could increase recession concerns for cyclical companies. The Healthcare sector tailwind depends on bellwethers such as UNH, JNJ, and LLY continuing to report strong results and guidance; weaker results could remove that support.
For the next 1 to 3 years, the thesis remains intact but mixed, with losses and earnings-miss risk weighing against recent relative financial performance and a supportive sector backdrop. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Birchtech Corp's published investment case. The stated target is sustain competitive advantages. |
| Intact |
| loses key patents or competitive advantages |
Qualitative: Patent victory secured News reports a patent victory in Q2 2026 and product momentum at a conference, supporting the maintenance of competitive advantages. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth must remain strong | A primary condition in Birchtech Corp's published investment case. The stated target is >=39% YoY. | Intact | falls below 30% YoY growth next fiscal year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.05 → $0.05 · observed estimates
$0.03B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-07 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-08 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-09 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-10 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-11 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-12 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-13 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-14 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-15 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-16 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-17 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-18 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-19 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-20 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-21 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-22 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-23 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-24 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-25 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-26 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-27 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-28 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-29 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-09-30 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-01 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-02 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-03 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-04 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-05 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-06 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-07 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-08 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-09 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-10 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-11 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-12 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-13 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-14 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-15 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-16 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-17 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-18 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-19 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-20 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-21 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-22 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-23 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-24 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-25 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-26 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-27 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-28 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-29 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-30 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-10-31 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-11-01 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-11-02 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-11-03 | $0.05 | $28,800,000 | 1 / 1 |
| 2026-11-04 | $0.05 | $28,800,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.